0001209191-23-056486.txt : 20231122 0001209191-23-056486.hdr.sgml : 20231122 20231122165150 ACCESSION NUMBER: 0001209191-23-056486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231120 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUGGENHIME ANDREW CENTRAL INDEX KEY: 0001230724 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 231434140 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-20 0 0001649094 Vaxcyte, Inc. PCVX 0001230724 GUGGENHIME ANDREW C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 President and CFO 1 Common Stock 2023-11-20 4 M 0 8000 5.35 A 87474 D Common Stock 2023-11-20 4 S 0 7876 51.12 D 79598 D Common Stock 2023-11-20 4 S 0 124 51.95 D 79474 D Stock Option (right to buy) 5.35 2023-11-20 4 M 0 8000 0.00 D 2030-05-11 Common Stock 8000 414827 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $50.76 to $51.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact 2023-11-22